Founded in 2014, Paradigm Biopharmaceuticals (ASX: PAR) is an Australian biopharmaceutical company which is involved in the research and development of therapeutic products for human use and it is focused on repurposing the drug pentosan polysulphate sodium to treat inflammation. Mr. Paul Rennie is the Managing Director of the company. The company is 517 Flinders Lane Level 2 Melbourne, VIC 3000, Australia.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK